Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara. [electronic resource]
Producer: 20170612Description: 442 p. digitalISSN:- 1475-2875
- Adjuvants, Immunologic -- administration & dosage
- Adolescent
- Adult
- Aluminum Hydroxide -- administration & dosage
- Antibodies, Protozoan -- blood
- Antigens, Protozoan -- genetics
- Double-Blind Method
- Drug-Related Side Effects and Adverse Reactions -- epidemiology
- Enzyme-Linked Immunosorbent Assay
- Female
- Gene Expression
- Genetic Vectors
- Healthy Volunteers
- Humans
- Immunoglobulin G -- blood
- Malaria Vaccines -- administration & dosage
- Male
- Mali
- Membrane Proteins -- genetics
- Middle Aged
- Pichia -- genetics
- Plasmodium falciparum -- genetics
- Protozoan Proteins -- genetics
- Recombinant Proteins -- genetics
- Vaccines, Subunit -- administration & dosage
- Vaccines, Synthetic -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.